Dhar, Chirag
Ramachandran, Prasanna
Xu, Gege
Pickering, Chad
Čaval, Tomislav
Wong, Maurice
Rice, Rachel
Zhou, Bo
Srinivasan, Apoorva
Aiyetan, Paul
Chu, Chih-Wei
Moser, Kaitlyn
Herzog, Thomas J.
Olawaiye, Alexander Babatunde
Jacob, Francis http://orcid.org/0000-0002-0446-1942
Serie, Daniel
Lindpaintner, Klaus
Schwarz, Flavio http://orcid.org/0000-0002-1060-1585
Funding for this research was provided by:
InterVenn Biosciences
Swiss Cancer Research foundation
Article History
Received: 8 September 2023
Revised: 22 February 2024
Accepted: 26 February 2024
First Online: 24 April 2024
Competing interests
: CD, PR, GX, CP, TC, MW, RR, BZ, AS, PA, CWC, KM, DS, KS and FS are or were employees of InterVenn, a company that discovers biomarkers and develops diagnostic tests. TJH received consulting fees from AZ, Caris, Clovis, Eisai, Epsilogen, Genelux, Genentech, GSK, Immunogen, J&J, Merck, Mersana, and Seagen. TJH also received support for attending meetings and/or travel from Alkermes and is on the leadership board of the GOG foundation. Additionally, TJH participated in a Data Safety Monitoring Board/Advisory Board with Corcept. ABO attended advisory board meetings for Merck, GSK, AZ, Genentech, Immunogen.
: All subjects gave written informed consent to participate. The study was approved by an institutional review board (WCG IRB 20223899 and WIRB IRB 20190246) and performed in accordance with the Declaration of Helsinki.